Allogene Therapeutics (ALLO) Depreciation & Amortization (CF) (2018 - 2026)

Allogene Therapeutics has disclosed Depreciation & Amortization (CF) across 9 years of filings, most recently posting $2.9 million for Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $2.9 million, down 7.42% year-over-year; the trailing twelve-month figure through Mar 2026 was $12.2 million (down 7.41% YoY), and the FY2025 annual result was $12.4 million, down 8.82% from the prior year.
• Depreciation & Amortization (CF) came in at $2.9 million for Q1 2026 at Allogene Therapeutics, down from $3.1 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $3.9 million in Q3 2022 to a low of $2.9 million in Q1 2026.
• The 5-year median for Depreciation & Amortization (CF) is $3.5 million (2023), against an average of $3.4 million.
• Peak annual rise in Depreciation & Amortization (CF) reached 92.49% in 2022, while the deepest fall reached 27.68% in 2022.
• Allogene Therapeutics' Depreciation & Amortization (CF) stood at $3.1 million in 2022, then advanced by 13.36% to $3.5 million in 2023, then decreased by 8.17% to $3.2 million in 2024, then retreated by 3.01% to $3.1 million in 2025, then declined by 7.39% to $2.9 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $2.9 million (Q1 2026), $3.1 million (Q4 2025), and $3.1 million (Q3 2025), per Business Quant data.